Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GZ17-6.02 in Advanced CRPC
NCT06636123Phase 1Recruiting
- Sponsor
- Virginia Commonwealth University
- Start
- Feb 2025
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gz17-6.02 in castration-resistant prostate cancer (CRPC), sponsored by Virginia Commonwealth University. Primary endpoint: Radiologic Progression-Free Survival up to 5 years. Started Feb 2025; status: recruiting.
02
Drugs
gz17-6.02
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT06636123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06636123.